123 related articles for article (PubMed ID: 38157042)
1. Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
Nirogi R; Ravula J; Benade V; Goyal VK; Pandey SK; Dogiparti D; Jayarajan P; Kalaikadhiban I; Jetta S; Palacharla VRC
Cancer Chemother Pharmacol; 2024 Mar; 93(3):253-264. PubMed ID: 38157042
[TBL] [Abstract][Full Text] [Related]
2. Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets.
Feng Z; Liu Y; Kuang Y; Yang S; Li J; Ye L; Huang J; Pei Q; Huang Y; Yang G
Drug Des Devel Ther; 2022; 16():3-12. PubMed ID: 35018094
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers.
Wang C; Hu C; Gao D; Zhao Z; Chen X; Hu X; Gong S; Li L; Zhang L
Cancer Chemother Pharmacol; 2019 Mar; 83(3):509-517. PubMed ID: 30535959
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of reference-scaled average bioequivalence of two oral formulations of abiraterone acetate in healthy Chinese subjects
.
Li C; Ding Y; Yang D; Wang M; Hu Y; Zhang H; Zhu X; Chen G; Li X; Wu M; Liu J; Chen H; Liu C; Shen Z; Liu B
Int J Clin Pharmacol Ther; 2018 Nov; 56(11):562-570. PubMed ID: 30220293
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.
Goldwater R; Hussaini A; Bosch B; Nemeth P
Clin Pharmacokinet; 2017 Jul; 56(7):803-813. PubMed ID: 28425029
[TBL] [Abstract][Full Text] [Related]
6. A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics.
Lubberman FJE; Benoist GE; Gerritsen W; Burger DM; Mehra N; Hamberg P; van Oort I; van Erp NP
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1179-1185. PubMed ID: 31515667
[TBL] [Abstract][Full Text] [Related]
7. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.
Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Molnár L; McDermott J; Zann V; Church A; Mair S; Filipcsei G; Heltovics G; Glavinas H
Cancer Chemother Pharmacol; 2017 Oct; 80(4):723-728. PubMed ID: 28776077
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers: An Open, Randomized, Single-Dose, Three-Period, Three-Sequence Crossover Study.
Wu ZX; Wang CJ; Shi P; Liu YP; Li T; Sun FF; Fu Y; Gao XM; Ma YP; Cao Y
Drugs R D; 2023 Jun; 23(2):121-127. PubMed ID: 37012461
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT
Nirogi R; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
Clin Drug Investig; 2021 May; 41(5):469-482. PubMed ID: 33788154
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles.
Boleslavská T; Rychecký O; Krov M; Žvátora P; Dammer O; Beránek J; Kozlík P; Křížek T; Hořínková J; Ryšánek P; Roušarová J; Canová NK; Šíma M; Slanař O; Štěpánek F
AAPS J; 2020 Sep; 22(6):122. PubMed ID: 32978690
[TBL] [Abstract][Full Text] [Related]
11. Comparative Pharmacokinetics and Bioequivalence Evaluation of Two Formulations of Pramipexole Dihydrochloride Extended-Release Tablets in Healthy Chinese Subjects Under Fasted and Fed States: A Randomized, Open-Label, Single-Dose, Two-Period Crossover Clinical Trial.
Yang L; Zhang L; Luo Z
Drug Des Devel Ther; 2023; 17():2369-2381. PubMed ID: 37600497
[TBL] [Abstract][Full Text] [Related]
12. Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects.
Jordán T; Basa-Dénes O; Angi R; Orosz J; Ötvös Z; Ujhelyi A; Filipcsei G; Molnár L; Solymosi T; Glavinas H; Capone D; Whitfield N; McDermott J; McKenzie L; Shurety L; Duus EM
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959452
[TBL] [Abstract][Full Text] [Related]
13. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
Yu A; Hazra A; Jiao JJ; Hellemans P; Mitselos A; Tian H; Ruixo JJP; Haddish-Berhane N; Ouellet D; Russu A
Clin Pharmacokinet; 2024 Apr; 63(4):511-527. PubMed ID: 38436924
[TBL] [Abstract][Full Text] [Related]
14. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
15. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety profile of desmopressin oral tablet formulations in healthy Chinese subjects under fasting and fed conditions.
Li X; Zhang H; Zhu X; Li C; Chen H; Liu J; Chen G; Wu M; Liu C; Shen Z; Niu J; Liu B; Ding Y
Int J Clin Pharmacol Ther; 2018 Sep; 56(9):434-442. PubMed ID: 30049304
[TBL] [Abstract][Full Text] [Related]
17. The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Kiyota T; Kambayashi A; Nishimura T
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):283-290. PubMed ID: 32618438
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
Sikes C; Stark JG; McMahen R; Engelking D
Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
[TBL] [Abstract][Full Text] [Related]
19. Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects.
Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Palacharla RC
Clin Drug Investig; 2018 May; 38(5):401-415. PubMed ID: 29380267
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects.
Kaeser B; Charoin JE; Gerber M; Oxley P; Birnboeck H; Saiedabadi N; Banken L
Int J Clin Pharmacol Ther; 2005 Mar; 43(3):154-62. PubMed ID: 15792400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
